Patients treated with satralizumab and immunosuppressant therapy were at less risk for neuromyelitis optica spectrum disorder relapse compared with patients treated with placebo, according to a study.
“A recently published clinical trial of satralizulmab, compared to placebo, demonstrated that blocking of IL-6 receptors is highly effective at preventing future relapses. Furthermore, satralizumab was well tolerated with a good safety profile that makes it an attractive long-term treatment option for NMOSD patients,” study co-author Anthony Traboulsee, MD, told Healio/OSN.
Researchers
Uncategorized